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INTRODUCTION
The legalization of medical cannabis has sparked intense debate
throughout the United States in recent years. While states such as Colorado
and Alaska have boldly legalized cannabis for recreational use,1 other states
have passed legislation that legalizes cannabis or some of its derivatives for
specified medical uses.2 Against the backdrop of federal illegality of cannabis
in all of its forms, states that have legalized medical cannabis have adopted
different regulatory systems that seem to have a common nucleus.
As of June 2017, twenty-nine states, the District of Columbia, Guam,
and Puerto Rico have legalized cannabis for medical use.3 An additional
sixteen states have legalized cannabidiol (CBD) oil for certain medical
conditions.4 CBD, unlike tetrahydrocannabinol (THC), is a non-psychoactive
part of the cannabis plant and is commonly used in an oil form.5 Thus, while
using cannabis that contains THC may have psychoactive as well as medical
effects on its users, users of CBD oil can still reap many of the medical
benefits of cannabis without experiencing the psychoactive effects resulting
from the THC.6 This key distinction may be the biggest reason many states
that have traditionally opposed legalizing cannabis for medical purposes
have legalized the use of CBD oil for limited medical purposes (commonly
for the treatment of epilepsy).7
In 2013, the Department of Justice released a memo stating it had
made a policy decision to not prosecute individuals lawfully using medical
cannabis under state law so long as those state systems conform to eight
1.
2.

COLO. CONST. art. XVIII, § 16(5)(a); ALASKA STAT. § 11.71.190 (1999).
See State Medical Marijuana Laws, NATIONAL CONFERENCE OF STATE
LEGISLATORS, http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx (last
visited Jan. 27, 2017).
3. See id.
4. See 16 States With Laws Specifically About Legal Cannabidiol (CBD), PROCON,
http://medicalmarijuana.procon.org/view.resource.php?resourceID=006473 (last visited Jan.
27, 2017).
5. See John Ingold, Non-Psychoactive CBD Oil Made From Marijuana Plants Poised
To Be Game-Changer (Oct. 2, 2016), http://www.denverpost.com/2014/03/29/nonpsychoactive-cbd-oil-made-from-marijuana-plants-poised-to-be-game-changer/.
6. Id.
7. See PROCON, supra note 4.
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general criteria (e.g., ensuring doctors do not participate in drug trafficking,
ensuring children do not have easy access to cannabis, etc.).8 This
announcement has led to persisting state experimentation in the area of
regulating cannabis for medical use.
States that have legalized some form of medical cannabis (“legalized
states”) have different systems of distribution. Nevertheless, most legalized
states have a reasonably similar system of regulation.9 Generally, patients
seeking to treat their health conditions with medical cannabis must go to a
health care professional with recommendation privileges (governed by state
statute) and get a recommendation from that professional to use medical
cannabis. Patients will only be able to get such a recommendation if they
have a “qualifying medical condition” listed by state statute. Once a patient
with a qualifying medical condition gets a recommendation from a privileged
health care professional, the patient usually must register with the state’s
Department of Health. All legalized states issue ID cards to patients upon
verification of a privileged physician’s recommendation, proof of in-state
residency, and payment of an application fee, and put the patient in a
confidential state registry containing all cardholders. For states that allow
qualifying minor children to use medical cannabis in some form, that minor
child must designate a “caregiver” (generally the child’s parent or legal
guardian), and the caregiver is the one to whom the ID card is assigned and
has the privilege of purchasing, possessing, and in some cases, cultivating
the medical cannabis. Adults may also appoint caregivers to assist them in
their treatment plans. Once a patient or her caregiver has an ID card, she may
go to an approved dispensary and purchase medical cannabis, subject to
certain possession limits and the presentation of her ID card. Generally,
dispensaries also must register with the state’s Department of Health, and
additional fees and licensure requirements apply to individuals seeking to
start a dispensary.10 Some states allow patients to personally cultivate
medical cannabis for their own use, again subject to certain restrictions.11
Patients generally must carry their ID cards with them while they are
traveling with medical cannabis in their possession. Finally, patients must
periodically renew their ID cards with a new recommendation from a
privileged health care professional and the payment of a renewal fee.12
A number of factors comprise the variations found in each
distribution system. This Note examines a variety of factors common to
existing state regulatory systems to identify the best ways to regulate the
distribution of medical cannabis. These factors include: (1) the number and
type of qualifying medical conditions, (2) patient access to medical cannabis
8.
9.

Guidance Regarding Marijuana Enforcement, Op. Att’y Gen. 1, 1-4 (2013).
See Medical Marijuana, THE NATIONAL ORGANIZATION FOR THE REFORM OF
MARIJUANA LAWS, http://norml.org/legal/medical-marijuana-2 (last visited Jan. 27, 2017).
10. Id.
11. Id.
12. Id.
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through personal cultivation and dispensaries, (3) privileged health care
professionals and recommendations of medical cannabis to patients, and (4)
patient registration requirements and state reciprocity. In analyzing each
factor, this Note discusses existing state systems that excel in relation to each
factor and existing state systems that perform poorly in relation to each
factor. Finally, this Note argues that the best regulatory scheme for the
distribution of medical cannabis is ultimately a mixture of several aspects of
existing systems and some aspects that no system has yet adopted. This Note
will also argue that this ideal regulatory system should be adopted by all
states to increase patient access and choice, decrease costs, improve
efficiency, and maximize the individual liberty for patients, while
simultaneously protecting the public.
The best regulatory system for the distribution of medical cannabis
should embody an expansive list of qualifying medical conditions with the
ability to be easily expanded as new medical and scientific discoveries
pertaining to the use of medical cannabis emerge. Second, the ideal
regulatory system should allow for personal cultivation and easy
establishment of dispensaries, so to improve patient access to medical
cannabis and achieve lower prices through market competition. Third, to
ensure patients have enough ascertainable health care professionals to serve
their needs, the model regulatory system should grant recommendation
privileges to a broad array of health care professionals that are easily
identified within the state through a published list of all professionals with
recommendation privileges. Finally, the ideal regulatory system should
include an efficient, cheap, and compassionate registration system through
low application fees and reciprocity provisions.
I.

MODEL ACT FOR STATE SYSTEMS OF DISTRIBUTION

(1) Purpose and Findings.13
(a) The recorded use of cannabis as medicine goes back nearly 5,000
years. Modern medical research has confirmed the beneficial uses of
cannabis in treating or alleviating the pain, nausea, and other symptoms
associated with a variety of debilitating medical conditions, including cancer,
multiple sclerosis, and HIV/AIDS, as found by the National Academy of
Sciences’ Institute of Medicine in March 1999.
(b) Studies published since the 1999 Institute of Medicine report
continue to show the therapeutic value of cannabis in treating a wide array of
debilitating medical conditions. These include relief of the neuropathic pain
caused by multiple sclerosis, HIV/AIDS, and other illnesses that often fail to
respond to conventional treatments and relief of nausea, vomiting, and other
13. This model section uses the statutory language found in § 5 of the Compassionate
Use of Medical Cannabis Pilot Program Act, the statute legalizing cannabis for medical
purposes in Illinois. 410 ILL. COMP. STAT. 130/5 (2016).
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side effects of drugs used to treat HIV/AIDS and hepatitis C, increasing the
chances of patients continuing on life-saving treatment regimens.
(c) Cannabis has many currently accepted medical uses in the United
States, having been recommended by thousands of licensed physicians to at
least 600,000 patients in states with medical cannabis laws. The medical
utility of cannabis is recognized by a wide range of medical and public health
organizations, including the American Academy of HIV Medicine, the
American College of Physicians, the American Nurses Association, the
American Public Health Association, the Leukemia & Lymphoma Society,
and many others.
(d) Data from the Federal Bureau of Investigation’s Uniform Crime
Reports and the Compendium of Federal Justice Statistics show that
approximately 99 out of every 100 cannabis arrests in the U.S. are made
under state law, rather than under federal law. Consequently, changing state
law will have the practical effect of protecting from arrest the vast majority
of seriously ill patients who have a medical need to use cannabis.
(2) Definitions.
(a) “Qualifying medical condition” means one or more of the
following:
(A) cancer, glaucoma, positive status for human
immunodeficiency virus, acquired immune deficiency syndrome,
hepatitis C, amyotrophic lateral sclerosis, Crohn’s disease, agitation
of Alzheimer’s disease, cachexia/wasting syndrome, muscular
dystrophy, severe fibromyalgia, spinal cord disease, including but
not limited to arachnoiditis, Tarlov cysts, hydromyelia,
syringomyelia, Rheumatoid arthritis, fibrous dysplasia, spinal cord
injury, traumatic brain injury and post-concussion syndrome,
Multiple Sclerosis, Arnold-Chiari malformation and Syringomyelia,
Spinocerebellar Ataxia (SCA), Parkinson’s, Tourette’s, Myoclonus,
Dystonia, Reflex Sympathetic Dystrophy, RSD (Complex Regional
Pain Syndromes Type I), Causalgia, CRPS (Complex Regional Pain
Syndromes Type II), Neurofibromatosis, Chronic Inflammatory
Demyelinating Polyneuropathy, Sjogren’s syndrome, Lupus,
Interstitial Cystitis, Myasthenia Gravis, Hydrocephalus, nail-patella
syndrome, residual limb pain, seizures (including those
characteristic of epilepsy), post-traumatic stress disorder (PTSD), or
the treatment of these conditions;14 or

14. This is the list of “debilitating medical conditions” found in § 10(h) of Illinois’
Compassionate Use of Medical Cannabis Pilot Program Act. 410 ILL. COMP. STAT. 130/10.
This is perhaps the largest statutory list of qualifying medical conditions currently available
in any legalized state.
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(B) Any other chronic or persistent medical symptom that
either:15
(i) Substantially limits the ability of the person to
conduct one or more major life activities as defined in the
Americans with Disabilities Act of 1990; or
(ii) If not alleviated, may cause serious harm to the
patient’s safety or physical or mental health.
(b) “Department of Health” means the governmental department and
any of its relevant agencies authorized to promulgate rules and regulations
pertinent to this Model Act.
(c) “Qualified individual” means an individual duly licensed and
authorized under the requirements of this Model Act to possess and purchase
medical cannabis in this state.
(d) “Registered dispensary” means a corporation, partnership,
limited liability company, or other legally authorized entity that acts as a
dispensary that meets the requirements of § 4 of this Model Act and
distributes medical cannabis in one or more of its forms.
(e) “Practitioner” means any physician licensed to practice medicine
in any state in the United States or any registered and licensed nurse
practitioner or any registered and licensed physician assistant in any state in
the United States.16
(f) “Recommendation privileges” means the right of a Practitioner to
provide a patient with a recommendation for medical cannabis within this
state.
(g) “Recommendation” means a recommendation to use medical
cannabis to a patient by a Practitioner for the treatment of the individual’s
qualifying medical condition.
(h) “Registered Identification Card” means an identification card
issued by the Department of Health to a Qualified Individual or the Qualified
Individual’s caregiver.
(3) Personal cultivation.17
(a) To cultivate cannabis in this state, a qualified individual must:
(A) Be twenty-one (21) years of age or older; and

15. This subsection is based on the statutory language found in CAL. HEALTH &
SAFETY CODE § 11362.7(12)(A)-(B) (West 2004), a part of California’s statutory scheme
defining “serious medical conditions.”
16. This definition is intended to extend recommendation privileges within the state to
nurse practitioners, physician assistants, or physicians that are licensed in any other state in
the United States.
17. This section’s language has been taken from OR. ADMIN. R. 333-008-0025 (2005)
and OR. ADMIN. R. 333-008-1030 (2005), part of Oregon’s regulatory scheme legalizing
medical cannabis, and modified to fit the purposes of the Model Act.
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(B) Not have been convicted of a Class A or Class B felony
under this state’s criminal code for the manufacture or delivery of a
controlled substance in Schedule I or Schedule II:
(i) Within the previous two years; or
(ii) More than once.
(b) In addition to the application review required by this state’s law,
the Department of Health must:
(A) Conduct a criminal background check on any individual;
(B) Verify the individual’s age;
(C) Verify the zoning of the grow site address if the grow
site is within city limits; and
(D) Determine the number of plants that are permitted at the
grow site address.
(c) Unless the Department of Health has received a request for a
grandfathered grow site address under state law, the grow site plant limits,
on and after March 1, 201718, are as follows:
(A) A maximum of twelve (12) mature marijuana plants if
the grow site location is within city limits and zoned residential; or
(B) A maximum of forty-eight (48) mature marijuana plants
if the grow site location is within city limits but not zoned residential
or outside city limits.
(4) Incorporation of Dispensaries.19
(a) To register a medical marijuana dispensary a person must:
(A) Submit an initial application on a form prescribed by the
Department of Health that includes but is not limited to:
(i) The name of the individual who owns the
dispensary or, if a business entity owns the dispensary, the
name of each individual who has a financial interest in the
dispensary;
(ii) The name of the individual or individuals
responsible for the dispensary, if different from the name of
the individual who owns the dispensary, with one of the
individuals responsible for the dispensary identified as the
primary person responsible for the dispensary;
(iii) The physical and mailing address of the medical
marijuana dispensary; and
(B) Application and registration fee.

18. This date could be changed by any state legislature adopting this Model Act to
reflect the date at which it wishes the new grow site plant limits to take effect.
19. This section is based on OR. ADMIN. R. 333-008-1020 (2005) and addresses the
requirements for the licensing of a dispensary as well as some areas where dispensaries are
not allowed.
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(b) An initial application for the registration of a dispensary must be
submitted electronically via the Department of Health’s website, [insert URL
to the State Department of Health’s website here]20.
(c) If an initial application is submitted along with the required fees,
the Department of Health will notify the applicant in writing that the
application has been received. Within thirty (30) calendar days of the mailing
of the written notice of acceptance, the following information must be
received by the Department of Health:
(A) For each individual named in the application:
(i) A legible copy of the individual’s valid
government issued photographic identification that includes
last name, first name, and date of birth;
(ii) Information, fingerprints, and fees required for a
criminal background check in accordance with this state’s
law; and
(iii) An individual history form and any information
identified in the form that is required to be submitted in
accordance with the rules promulgated by the Department of
Health;
(B) A written statement from an authorized official of the
local government that the proposed location of the dispensary is not
located in an area that is zoned for residential use as that term is
defined in under this state’s law;
(C) Proof that the business is registered or has filed an
application to register as a business with this state’s Office of the
Secretary of State, including proof of registration for any doing
business as (DBA) registration;
(D) Documentation, in a format prescribed by the Authority,
that the proposed location of the dispensary is not within 1,000 feet
of:
(i) The real property comprising a public or private
elementary or secondary school, except as otherwise
provided by the laws of this state; or
(ii) A registered dispensary.
(E) A scaled site plan of the parcel on which the premises
proposed for registration is located, including:
(i) Cardinal directional references;
(ii) Bordering streets and the names of the streets;
(iii) Identification of the building or buildings in
which the proposed dispensary is to be located;
(iv) The dimensions of the proposed premises of the
dispensary;

20. The URL for the state’s Department of Health should be inserted here.
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(v) Identification of other buildings or property
owned by or under the control of the applicant on the same
parcel or tax lot as the premises proposed for registration that
will be used in the business; and
(vi) Identification of any residences on the parcel or
tax lot.
(F) A scaled floor plan of all enclosed areas of the premises
at the proposed location that will be used in the business with clear
identification of walls, partitions, counters, windows, all areas of
ingress and egress, intended uses of all spaces and all limited access
areas; and
(G) Documentation that shows the applicant has lawful
possession of the proposed location of the dispensary.
(d) The Department of Health shall have the authority to promulgate
all rules and regulations pertaining to the fee schedule for applications under
this section, provided that the fee for an application under this section shall
not exceed $4,000.
(5) Practitioner Recommendation Privileges.
(a) Any Practitioner has the privilege to recommend medical
cannabis to a patient who is domiciled in this State and has a qualifying
medical condition within the meaning of this Model Act.21
(b) The Department of Health shall, on its Internet website, publish
and maintain a current list of all Practitioners within this state that have
recommendation privileges under this Model Act.22
(6) Registered Identification Cards and Reciprocity.
(a) An individual shall not be exempt from criminal penalties for
possession or cultivation of marijuana in this state unless such individual
registers with the Department of Health after receiving a Recommendation
from a Practitioner and receives a Registered Identification Card from the
Department of Health.23
(b) Upon presentation of a valid in-state photo ID, a $25 registration
fee, and a Practitioner’s Recommendation, the Department of Health shall
issue the presenting individual (or, if the Recommendation is for a minor, to
the caregiver) a Registered Identification Card. A Registered Identification
Card expires two (2) years after it is issued.
21. This provision is intended to automatically grant recommendation privileges to
physicians, registered nurse assistants, and physician assistants duly licensed and registered
in any state in the United States.
22. This section is intended to ensure that a state’s Department of Health will publish a
current list of all practitioners within the state who have recommendation privileges.
23. This provision is intended to only give criminal protection to Qualified Individuals
within the meaning of the Model Act.
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(c) A Qualified Individual or a Qualified Individual’s caregiver may
renew an expired Registered Identification Card by presenting a valid in-state
photo ID, a $25 renewal fee, and a Practitioner’s Recommendation to the
Department of Health.
(d) Notwithstanding the other provisions of this Model Act, if a
Practitioner determines that an individual’s qualifying medical condition is
incurable and permanent, a Registered Identification Card issued to such
individual shall not expire.
(e) The Department of Health shall not issue a Registered
Identification Card to an individual under the age of eighteen (18). If an
individual under the age of eighteen (18) presents two (2) Recommendations
from two (2) different Practitioners and designates a parent or guardian as a
caregiver to the Department of Health, the Department of Health shall issue
a Registered Identification Card to the designated caregiver of such
individual at no cost. A Registered Identification Card issued under this
subsection shall expire six (6) months after it is issued, and may only be
renewed in the same manner that it is issued.24
(f) A registry identification card, or its equivalent, that is issued
under the laws of another state, district, territory, commonwealth, or insular
possession of the United States that allows the medical use of marijuana by
a visiting qualifying patient, or allows a person to assist with a visiting
qualifying patient’s medical use of marijuana, shall have the same force and
effect as a registry identification card issued by the department.25
(g) Notwithstanding the other provisions of this Model Act, a valid
registry identification card under the laws of another state shall not receive
reciprocity in this state unless the health care professional that issued the
certification or recommendation for the out-of-state registry identification
card would be considered a Practitioner within this State.26
II.
A.

AREAS OF AGREEMENT AND DISAGREEMENT AMONG
LEGALIZED STATES

Variations Among Legalized States Regarding the Number and
Type of Qualifying Medical Conditions

One of the most fundamental aspects of any regulatory system for
the distribution of medical cannabis is the list of medical conditions that
allow patients to use cannabis legally. Often called “qualifying medical

24. This section is intended to embody the additional safety protections for minor
patients that this paper discusses.
25. This subsection is based on MICH. COMP. LAWS ANN. § 333.26424(k) (West 2016),
part of Michigan’s regulatory scheme for medical cannabis.
26. This provision is intended to ensure that out-of-state identification cards will only
receive reciprocity if the health care professional that issued the recommendation for it in the
other state would have been considered a Practitioner within the meaning of the Model Act.
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conditions,” “debilitating medical conditions,” or “qualifying health
conditions,” this list, usually created by statute, ballot initiative, or
regulation, determines which health conditions qualify any given patient for
the use of medical cannabis in that state.27 While having a larger and more
numerous list is not necessarily indicative of a superior distribution system,
it does generally indicate that patients in states with broader lists will have a
better chance at getting access to medical cannabis.28 Indeed, it seems
axiomatic that any regulatory system for the distribution of medical cannabis
should place the ability of patients to use cannabis to treat their health
conditions as one of its highest priorities.29
Every legalized state lists cancer and HIV/AIDS as a qualifying
medical condition.30 Most legalized states also list cachexia (wasting
syndrome), glaucoma, multiple sclerosis, and epilepsy and other seizure
disorders as qualifying medical conditions.31 A handful of legalized states list
post-traumatic stress disorder (PTSD) as a qualifying medical condition, and
a few states list severe pain, nausea, or terminal illness as qualifying medical
conditions.32 New Mexico law states that hospice patients are automatically
considered to have a qualifying medical condition,33 and the District of
Columbia catalogs “any condition for which treatment with medical
marijuana would be beneficial, as determined by the patient’s physician” as
a qualifying medical condition.34
Illinois has perhaps the largest and most inclusive list of qualifying
medical conditions, encompassing forty different diseases and disorders that
allow patients to utilize medical cannabis to treat their health conditions. 35
Lupus, Lou-Gehrig’s Disease (ALS), muscular dystrophy, and Parkinson’s
disease are all included in Illinois’ list, as are spinal cord injuries and Tourette
syndrome.36 Noticeably absent from Illinois’ list is a qualifying health
condition for chronic or severe pain, a broader category that California,
Arizona, and others have adopted.37
Another interesting legalized state in terms of its qualifying medical
conditions is California. The Compassionate Use Act of 1996—also known
27. Andrew J. Boyd, Medical Marijuana and Personal Autonomy, 37 J. MARSHALL L.
REV. 1253, 1258-69 (2004).
28. See id.
29. Patient Access to Medical Marijuana in Washington State, WASH. STATE DEP’T OF
HEALTH, at 20 (2008).
30. 28 Legal Medical Marijuana States and DC, PROCON, http://medicalmarijuana
.procon.org/view.resource.php?resourceID=000881&print=true (last visited Jan. 27, 2017).
31. Id.
32. Id.
33. N.M. CODE R § 7.34.3.7 (LexisNexis 2015).
34. D.C. CODE § 7-1671.01(17) (2015).
35. 410 ILL. COMP. STAT. 130/10 (2016).
36. Id.
37. CAL. HEALTH & SAFETY CODE § 11362.7(h)(6) (West 2004); ARIZ. REV. STAT.
§ 36-2801(3)(b) (LexisNexis 2010); N.H. REV. STAT. ANN. §126-X:1(IX)(a)(2) (2016); OR.
REV. STAT. § 475B.410(6)(b)(B) (2016).
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as Proposition 215, a successful ballot initiative—allows Californians to use
medical cannabis upon the recommendation of a physician for the treatment
of cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis,
migraine, or “any other illness for which marijuana provides relief.”38 The
last item in the list, “[a]ny other chronic or persistent medical symptom that
either: (A) substantially limits the ability of the person to conduct one or more
major life activities as defined in the Americans with Disabilities Act of
1990 . . . (B) [or] [i]f not alleviated, may cause serious harm to the patient’s
safety or physical or mental health,” offers patients unique latitude for
acquiring medical cannabis to treat a vast array of health conditions. 39 A
plethora of various health conditions could theoretically constitute a
qualifying medical condition under the California statute.
The most restrictive legalized state’s list of qualifying medical
conditions is probably that of New Hampshire’s, which allows patients to use
medical cannabis for only chronic or terminal diseases, cachexia, severe pain,
nausea, vomiting, seizures, and severe, persistent muscle spasms. While only
seven conditions are listed as qualifying medical conditions under New
Hampshire’s list, it is noteworthy that the list includes severe pain as a
qualifying medical condition—a condition that is not on Illinois’ list.40
B.

The Ideal Regulatory System’s Rules Pertaining to the Number
and Type of Qualifying Medical Conditions

State regulatory systems with the greatest numbers of qualifying
medical conditions give a more expansive number of patients the best
opportunities to use medical cannabis to treat their medical conditions.41
Thus, patients living under state distribution systems with more qualifying
medical conditions have greater choice in treatment plans than those living
under state distribution systems with a smaller number of qualifying medical
conditions.42 While the advantages of greater patient choice remain unclear
in certain respects, at least some patients are likely able to use medical
cannabis instead of conventional pharmaceutical drugs, particularly
opioids.43 This may mean that patients could use medical cannabis as an
alternative to potentially more expensive pharmaceutical drugs that also
carry unwanted side-effects, including higher risks of addiction.44 Indeed, in
light of the recent media coverage of the opioid epidemic sweeping the
38. CAL. HEALTH & SAFETY CODE § 11362.7(h)(12)(A)-(B) (West 2004).
39. Id.
40. N.H. REV. STAT. ANN. § 126-X:1(IX.)(a) (2016); 410 ILL. COMP. STAT. 130/10
(2016).
41. Clinical Implications and Policy Considerations of Cannabis Use, AMA,
https://assets.ama-assn.org/sub/meeting/documents/i16-resolution-907.pdf (last visited Jan.
27, 2017).
42. Boyd, supra note 27, at 1278.
43. Id.; See also AMA, supra note 41.
44. Boyd, supra note 27, at 1278; See also AMA, supra note 41.

2018]

FLYING HIGH IN THE REGULATORY STATE

265

United States, medical cannabis appears increasingly more attractive as a
substitute treatment option for patients who would otherwise treat their health
conditions using opioids.
The best regulatory system for the distribution of medical cannabis
should encompass a broad list of qualifying medical conditions to allow
patients greater diversity in their treatment options. Allowing for more
qualifying medical conditions for patient access to medical cannabis could
save patients money in treating their health conditions or reduce traditional
risks associated with prescription drugs.45 Particularly in the area of chronic
pain, using medical cannabis as an alternative to prescription opioids could
reduce the risk of drug addiction and lead to better treatment outcomes for
patients.46
Accordingly, Illinois’ list of qualifying medical conditions is
probably the best list currently existing in the United States. An ideal
regulatory system for distributing medical cannabis would adopt a list similar
to Illinois’, with an eye toward expanding the list of qualifying medical
conditions when any future medical research identifies new medical
conditions that, with reasonable certainty, could be treated successfully with
medical cannabis. Finally, the preferred list of qualifying medical conditions
should include a provision like that found in California, giving privileged
health care professionals broad discretion to recommend medical cannabis to
patients for other health conditions not specifically enumerated in the list of
qualifying health conditions, so long as the physician has reason to believe
that medical cannabis could help treat the patient’s health condition within
her sound medical judgment. Including such a provision in a state’s
regulatory system for the distribution of medical cannabis could encourage
health care professionals to engage in innovative treatment plans and
participate in new research and development projects exploring the
additional uses and safety risks of using medical cannabis.47
C.

Variations Among Legalized States Regarding Patient Access
to Medical Cannabis Through Personal Cultivation and
Dispensaries

Another important aspect of any state’s regulatory system for the
effective distribution of medical cannabis is a patient’s access to medical
cannabis, either through personal cultivation or in-person purchases from
approved dispensaries.48 Some states, such as New York, have restrictive

45. Boyd, supra note 27, at 1278; See AMA, supra note 41.
46. LESTER GRINSPOON & JAMES B. BAKALAR, MARIHUANA: THE FORBIDDEN
MEDICINE 110 (rev. ed. 1997).
47. INSTITUTE OF MEDICINE, MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE
177 (Janet E. Joy, et al. eds., 1999).
48. See Karen O’Keefe, State Medical Marijuana Implementation and Federal Policy,
16 J. HEALTH CARE L. & POL’Y 39, 50-57 (2013).
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systems that do not allow for personal cultivation and only allow purchases
at a limited number of dispensaries throughout the state.49 Other states, such
as Colorado and Oregon, employ the opposite approach, allowing patients to
cultivate a certain amount of their own medical cannabis or purchase medical
cannabis at a large number of different dispensaries sprawled throughout
each respective state.50
Oregon currently has 521 dispensaries throughout the state where
patients can obtain cannabis.51 In addition, Oregonian patients can cultivate
up to twelve plants in residential zones and forty-eight plants in nonresidential zones, provided that they register as a grower for only themselves
and meet certain criteria (a patient must be twenty-one years of age or older,
not have been convicted of a Class A or Class B felony for the manufacture
or delivery of a controlled substance in the previous two years or more than
once, and pass a criminal background check).52 Individuals seeking to apply
for licenses to create medical cannabis dispensaries in Oregon must pay a
$4,000 application fee, get fingerprinted, and pass a criminal background
check.53 Finally, a dispensary may not be located in a residential zone, within
1,000 feet of a school, or within 1,000 feet of another medical marijuana
dispensary.54
Colorado currently has 525 dispensaries throughout the state,55 and
patients or their caregivers can jointly cultivate up to six plants.56 Colorado
permits three different kinds of medical cannabis dispensaries: (1) “Center
Type I,” which may serve 1-300 patients and costs $9,000 to apply for and
obtain state licensing; (2) “Center Type II,” which may serve 301-500
patients and costs $16,000 to apply for and obtain state licensing; and (3)
“Center Type III,” which may serve 501 or more patients and costs $22,000
to apply for and obtain licensing.57
In stark contrast to Oregon and Colorado, both of which contain
hundreds of dispensaries throughout their respective states, New York
currently has only twenty dispensaries throughout the entire state, and only

49. N.Y. PUB. HEALTH LAW § 3364 (McKinney 2014).
50. COLO. REV. STAT. ANN. § 18-18-406 (2016); OR. REV. STAT. § 475B.428 (2016).
51. Oregon Health Authority, Approved Marijuana Licensed Retailers, OREGON.GOV,
http://www.oregon.gov/olcc/marijuana/pages/default.aspx (last visited Feb. 21, 2018).
52. OR. ADMIN. R. 333-008-0025 (2005).
53. OR. ADMIN. R. 333-008-1030; OR. ADMIN. R. 333-008-2020.
54. OR. ADMIN. R. 333-008-1110.
55. Colo. Dep’t of Revenue, MED Licensed Centers as of January 5, 2017,
COLORADO.GOV, https://www.colorado.gov/pacific/sites/default/files
/Centers%2001052017.xlsx (last visited Feb. 21, 2018).
56. COLO. REV. STAT. § 18-18-406(3)(b)(I)–(II) (2013).
57. Colo. Dep’t of Revenue, Application and Licensing – Marijuana Enforcement,
COLORADO.GOV, https://www.colorado.gov/pacific/sites/default/files/ MED%20Fee%
20Table%20Color%20May%202017%20%281%29.pdf (last visited Jan. 5, 2017); See also
COLO. CONST. art. IIXX, § 16(5)(a).
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ten companies have been approved to operate those dispensaries.58 In fact,
under New York’s current statutory regime, no more dispensaries can
currently be created.59 In addition, New York imposes heavy application and
registration fees for companies wishing to open a medical cannabis
dispensary–companies must pay a non-refundable $10,000 application fee
and a $200,000 registration fee (the registration fee is refunded if the
company is denied registration).60 Finally, New York does not allow patients
to personally cultivate medical cannabis.61
In keeping with New York, Illinois has only forty-seven dispensaries
located throughout the state, and patients may only purchase medical
cannabis from one dispensary at a time.62 Patients must select the dispensary
they wish to use and register it with the Illinois Department of Health;
patients may change their dispensary later on, but patients have to fill out a
form to change their dispensary and the change must also be registered with
the Illinois Department of Health before it becomes effective.63 The Illinois
Department of Health must approve individuals wanting to open a
dispensary, and such individuals must pay a $5,000 application fee and a
$30,000 registration fee.64 In addition, annual renewal fees for dispensaries
total $25,000.65 The enabling statute, the Compassionate Use of Medical
Cannabis Pilot Program Act, sunsets on July 1, 2020, and does not allow for
more than a total of sixty dispensaries throughout the state.66 Finally, and
perhaps most significantly, neither Illinois nor New York allows patients to
personally cultivate medical cannabis.67

58. New York State Medical Marijuana Program: Registered Organizations, N.Y.
STATE, https://www.health.ny.gov/regulations/medical_marijuana/application/
selected_applicants.htm (last visited Feb. 21, 2018).
59. N.Y. PUB. HEALTH LAW § 3365(9) (2014). See Medical Marijuana Program
Applications, N.Y. STATE DEP’T OF HEALTH, https://www.health.ny.gov/regulations/
medical_marijuana/application/applications.htm (last visited Jan. 27, 2017).
60. Instructions for Application or Registration as a Registered Organization, N.Y.
STATE DEP’T OF HEALTH, https://www.health.ny.gov/regulations/medical_marijuana/
docs/app_instructions.pdf (last visited Jan. 27, 2017).
61. N.Y. COMP. CODES R. & REGS. tit. 10, § 1004.21 (2015).
62. Licensed Medical Cannabis Dispensaries, ILL. DEP’T OF FIN. AND PROF. REG.,
http://www.idfpr.com/Forms/MC/ListofLicensedDispensaries.pdf (last visited Jan. 27,
2017).
63. Id.
64. Joint Committee on Administrative Rules, Fees, ILL. GEN. ASSEMBLY,
http://www.ilga.gov/commission/jcar/admincode/068/068012900C00800R.html (last visited
Jan. 27, 2017).
65. Id.
66. 410 ILL. COMP. STAT. 130/220, 130/115 (2016).
67. See 410 ILL. COMP. STAT. 130/10.
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The Ideal Regulatory System’s Rules Pertaining to Patient
Access to Medical Cannabis Through Personal Cultivation and
Dispensaries

An examination of Colorado, Oregon, New York, and Illinois
illuminates the spectrum of efficiency of state regulatory attempts for the
distribution of medical cannabis in terms of personal cultivation and
dispensary facilities. Both Colorado and Oregon have hundreds of
dispensaries throughout their respective states, and applying for and
registering a new dispensary is relatively cheap. Additionally, both Colorado
and Oregon allow for some kind of personal cultivation, with Oregon’s
system being particularly generous for patients with a “green thumb.”
Illinois, on the other hand, requires significant capital to start a dispensary
and can only have sixty dispensaries by statute. New York is even more
restrictive on both of these points, since it only allows one-third the number
of dispensaries as Illinois, and requires even more capital to start a
dispensary. Moreover, both Illinois and New York prohibit personal
cultivation, which may restrict access to medical cannabis for poorer
individuals.68
The best regulatory system should adopt an approach similar to
Colorado’s or Oregon’s pertaining to the issues of personal cultivation and
dispensary registration, because allowing for more dispensaries is likely to
reduce the geographical distances patients will need to travel to purchase
medical cannabis, and encourage more efficient practices for delivery of
medical cannabis to patients at individual dispensaries through market
competition and banking services.69 In addition, allowing patients to cultivate
their own medical cannabis could give poorer or extremely sick patients a
cheaper and easier alternative for acquiring the necessary medical cannabis
to treat their conditions.70 Nevertheless, even a free market approach to
distribution should have enough regulation to ensure that only qualifying
patients can purchase medical cannabis and that patients cannot acquire more
medical cannabis than they are allowed to purchase at any given time. If these
bare-bones regulations did not exist in a state’s regulatory system for the
distribution of medical cannabis, that state may risk the DOJ enforcing
federal marijuana prohibition in that state, as the 2013 DOJ memo on this
topic suggests.71
Several additional factors support the notion that the ideal regulatory
system should reflect that of Colorado’s or Oregon’s. First, allowing personal
68. See Walt Hickey, Medical Marijuana is Still the Best Deal in Colorado,
FIVETHIRTYEIGHT (Apr. 29, 2014), https://fivethirtyeight.com/features/medical-marijuana-isstill-the-best-deal-in-colorado.
69. David Bronfein, Maryland State Bank: The Responsible Solution for Fostering the
Growth of Maryland’s Medical Cannabis Program, 47 U. BALT. L.F. 28, 56 (2016).
70. Boyd, supra note 27, at 1285-86.
71. See Guidance Regarding Marijuana Enforcement, supra note 8.
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cultivation for patients is a crucial aspect of the most effective regulatory
system for medical cannabis. Allowing personal cultivation would likely
expand patient access to medical cannabis because it allows for poorer
individuals or individuals unable to travel to dispensaries to grow their own
cannabis instead of purchasing it.72 Personal cultivation also increases patient
choice, since patients can elect to grow their own cannabis in customized
amounts or types (so long as the individual does not exceed the statutory
limits or requirements) and at times that are more convenient to them.73 Some
patients may also have qualifying medical conditions that make it difficult
for them to travel to dispensaries or caregiver arrangements that make it
difficult for them to regularly get the medical cannabis they need from
dispensaries to treat their health conditions. Personal cultivation could
provide an alternative to patients in these situations, especially if they are an
adult and are unable to secure a caregiver to assist them.
Second, the most effective regulatory system for distributing medical
cannabis should provide for an easy, cheap, and efficient process for
individuals and companies to open new dispensaries. While the regulations
should incorporate criminal background checks and certain licensing and
zoning requirements on aspiring dispensary owners (as Colorado and Oregon
do, for example) to protect the public,74 the application, registration, and
renewal fees for dispensaries should not be unreasonable. It appears that the
more capital a state requires for dispensaries to open and operate, the more
likely it is that that state will have fewer dispensaries and less industry
growth.75 Geographically large or populous states are likely to need a
substantial number of dispensaries to provide adequate access to medical
cannabis for patients.76 To the extent that patients have to travel long
distances to reach a dispensary, or there are not enough dispensaries to meet
patient needs in a geographic area, patient choice and access is undermined.77
Additionally, if there are too few dispensaries throughout a state, a lack of

72. But see Vicky Uhland, The Truth About Growing Your Own Pot, THE DENVER
POST (Feb. 22, 2013), http://www.denverpost.com/2013/02/22/marijuana-the-truth-aboutgrowing-your-own-pot.
73. Id.
74. AMA, supra note 41.
75. Compare New York State Medical Marijuana Program, N.Y. STATE, https://www
.health.ny.gov/regulations/medical_marijuana/ (20 dispensaries, 1,469 registered
practitioners, and 45,350 patients throughout New York as of February 21, 2018) with Colo.
Dep’t of Revenue, Medical Marijuana Centers, COLORADO.GOV, https://www.colorado
.gov/pacific/sites/default/files/Centers%2001052017.xlsx (525 dispensaries as of February
21, 2018).
76. See Tess Owen, How New York Totally Screwed Up Legalizing Medical
Marijuana, VICE NEWS (Jan. 11, 2016), https://news.vice.com/article/how-new-york-totallyscrewed-up-legalizing-medical-marijuana (finding that with the restrictive number of only
20 dispensaries throughout all of New York, there is only one dispensary for every 2,700
square miles).
77. Id.
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supply or competition may drive up the price of medical cannabis, thus
further undermining patient access through prohibitive prices.78
Third and finally, the best regulatory system should avoid statutory
limits on the number of dispensaries that a state can have unless there is a
compelling reason to do so. Allowing for dynamic growth in a state’s number
of dispensaries is more likely to increase patient choice and access because
of increased market competition, greater medical cannabis supply, and
broader geographic coverage.79 While some state regulatory systems may
wish to ensure that a particular geographic area does not become flooded with
dispensaries, this mechanism could be accomplished by regulating
dispensaries in a similar way as hospitals–states could require dispensaries
to acquire a certificate of need for a particular geographic region before
allowing them to open.80 This kind of approach—requiring a certificate of
need for dispensaries to open rather than imposing a flat statutory maximum
on the number of dispensaries allowed to operate in the state—is more
particularized and still likely to accomplish the goal of preventing an
undesirable flood of dispensaries in any one geographic region.81
E.

Variations Among Legalized States Regarding Privileged
Health Care Professionals and Recommendations of Medical
Cannabis to Patients

Under the federal Controlled Substances Act, cannabis is a Schedule
I substance–the same scheduling as heroin, ecstasy, and LSD.82 A Schedule
I substance is a substance that (1) “has a high potential for abuse,” (2) “has
no currently accepted medical use in treatment in the United States,” and (3)
“[has] a lack of accepted safety for use of the drug or other substance under
medical supervision.”83 Thus, in legalized states, health care professionals do
not directly prescribe cannabis to patients. Instead, legalized states generally

78. See Hickey, supra note 68; See also ADAM SMITH, THE WEALTH OF NATIONS 79
(1776).
79. See Hickey, supra note 66; See also ADAM SMITH, THE WEALTH OF NATIONS 79
(1776).
80. For example, Tennessee law states that “[n]o certificate of need shall be granted
unless the action proposed in the application is necessary to provide needed health care in
the area to be served, can be economically accomplished and maintained, will provide health
care that meets appropriate quality standards and will contribute to the orderly development
of adequate and effective health care facilities or services.” TENN. CODE ANN. § 68-111609(b) (West 2016).
81. Owen, supra note 76. Of course, requiring that dispensaries be a certain distance
away from each other may often serve as a de facto limitation on the number of overall
dispensaries in any given state. Nevertheless, limiting the number of dispensaries by
geographic region and demand within that region would likely still prove more effective
than the debilitating (and often arbitrary) limitation on the number of dispensaries via a flat
statutory maximum
82. Schedule I, 21 C.F.R. § 1308.11 (2017).
83. 21 U.S.C. § 812(b)(1) (2012).
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require recommendations or certifications of medical cannabis to patients
with a qualifying medical condition from health care professionals with
recommendation privileges.84
Physicians have a First Amendment right to recommend medical
cannabis to patients within honest medical judgment made in good faith.85 In
Conant v. Walters, California physicians had recommended medical
cannabis to patients under the Compassionate Use Act of 1996. The DEA
had stated that it would seek enforcement actions against the recommending
physicians–specifically, the DEA threatened revocation of the physicians’
registration to write prescriptions for controlled substances.86 The physicians
and their patients receiving the recommendations mounted a class action First
Amendment challenge to the DEA’s response to the Compassionate Use
Act.87 The United States District Court for the Northern District of California
held in favor of the physicians and patients, reasoning that the doctrine of
constitutional doubt protected a physician’s right to recommend medical
cannabis to qualifying patients based on his honest medical judgment made
in good faith.88 The United States Court of Appeals for the Ninth Circuit
affirmed, further emphasizing that the government could not prohibit a
physician from speaking about the medical benefits of marijuana with his
patient because the prohibition targeted the physician’s speech on content
and viewpoint grounds.89
Legalized states differ in their regulations concerning health care
professionals recommending medical cannabis to patients, but their
differences concerning this issue are less pronounced than in other legal
issues related to regulating medical cannabis. State differences in this area
mainly focus on what types of health care professionals are allowed to
recommend medical cannabis to patients and whether health care
professionals must register with the state in order to obtain recommendation
privileges.90 The existence of a physician-patient relationship is generally
required for a physician to recommend medical cannabis to a patient.91
In New York, for example, any physician licensed in the state and in
good standing may recommend medical cannabis to patients, so long as they
also comply with the course and registration requirements.92 Specifically,
New York physicians must pay $250 and complete a 4-hour course before
registering with the New York Department of Health to qualify for medical

84. See PROCON, supra note 30.
85. See Conant v. Walters, 309 F.3d 629, 637 (9th Cir. 2002).
86. Id. at 632.
87. Id. at 634.
88. Conant v. McCaffrey, No. C 97-00139 WHA, 2000 WL 1281174, at *16 (N.D.
Cal. Sept. 7, 2000).
89. Walters, 309 F.3d at 637.
90. See NAT’L CONFERENCE OF STATE LEGISLATORS, supra note 2.
91. See Walters, 309 F.3d at 636.
92. N.Y. COMP. CODES R. & REGS. tit. 10, § 1004.1(a) (2015).
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cannabis recommendation privileges.93 As of June 6, 2017, only 1,043
physicians in New York have medical cannabis recommendation
privileges.94 Because of the small number of physicians that have fulfilled
the statutory requirements to receive recommendation privileges and the lack
of a published list of physicians with recommendation privileges whom do
not wish to be published on the list, many patients in New York have
complained of difficulty in finding a physician that can recommend medical
cannabis to them.95 Indeed, this may explain why barely 21,000 patients in
New York have currently taken advantage of medical cannabis to treat their
debilitating health conditions.96 Nevertheless, some private organizations are
taking steps to list privileged New York physicians on the Internet, and this
may prove useful to some New York patients.97
In Arizona, any doctor of medicine (MD), doctor of osteopathy
(DO), naturopathic physician (ND), or homeopathic physician (MD(H) or
DO(H)) who is licensed in the state and in good standing may recommend
medical cannabis to patients.98 A physician’s recommendation takes the form
of a written certification by the physician to the patient in the course of the
physician-patient relationship, and certifies that “in the physician’s
professional opinion the patient is likely to receive therapeutic or palliative
benefit from the medical use of marijuana to treat or alleviate the patient’s
debilitating medical condition or symptoms associated with the debilitating
medical condition.”99
Some states broaden the scope of individuals who can recommend
medical cannabis to patients with qualifying health conditions. New Mexico,
for example, allows any “person licensed in New Mexico to prescribe and
administer drugs that are subject to the Controlled Substances Act” to
recommend medical cannabis to qualifying patients.100 Thus, MDs, DOs, and
nurse practitioners and physician’s assistants may recommend medical
cannabis in New Mexico. Washington also broadens the scope of individuals
with recommendation privileges in a similar fashion.101
In addition, Rhode Island and Vermont allow certain licensed
healthcare professionals from other states to recommend medical cannabis to
93. Id.
94. New York State Medical Marijuana Program, N.Y. DEP’T OF HEALTH,
https://www.health.ny.gov/regulations/medical_marijuana (last visited June 6, 2017).
95. Caroline Lewis, Patients Say They Can’t Find A Medical-Marijuana Doc In New
York (Feb. 4, 2016), http://www.crainsnewyork.com/article/20160204/HEALTH
_CARE/160209928/its-tough-finding-a-new-york-doc-who-can-administer-medicalmarijuana.
96. N.Y. DEP’T OF HEALTH, supra note 94.
97. New York Medical Marijuana Doctors, MARIJUANA DOCTORS,
https://www.marijuanadoctors.com/medical-marijuana-doctors/NY (last visited Jan. 27,
2017).
98. ARIZ. REV. STAT. ANN. § 36-2801(12) (2010).
99. Id. § 36-2801(18).
100. N.M. STAT. ANN. § 26-2B-3 (2007).
101. WASH. REV. CODE § 69.51A.010(5) (2016).
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qualifying patients within their respective states. Rhode Island allows any
licensed physician in good standing from Rhode Island, Massachusetts, or
Connecticut to recommend medical cannabis to qualifying patients.102 Rhode
Island also extends recommendation privileges to physician assistants and
registered nurse practitioners from within Rhode Island, a similar extension
to those seen in New Mexico and Washington.103 Vermont gives
recommendation privileges to any licensed MD, DO, ND, physician’s
assistant, or advanced practice registered nurse in good standing from
Vermont, New Hampshire, Massachusetts, or New York, thereby
incorporating a broader scope of individuals with recommendation privileges
from within and outside the state.104
F.

The Ideal Regulatory System’s Rules Pertaining to Privileged
Health Care Professionals and Recommendations of Medical
Cannabis to Patients

The best regulatory system for distributing medical cannabis should
emulate Vermont’s or Rhode Island’s regulatory system while taking care to
avoid the burdensome regulations found in New York’s regulatory system.
Indeed, New York’s onerous regulations that require physicians to pay a fee
and take a course to gain recommendation privileges may be one reason why
there appears to be a shortage of physicians in New York with
recommendation privileges.105 Additionally, New York’s statutory refusal to
publish a list of non-consenting physicians with recommendation privileges
gives rise to additional barriers to patient access and choice, since patients
simply cannot find a physician who can recommend medical cannabis to
them legally.106 The optimal design of a regulatory system for distributing
medical cannabis should be to protect the interests of patients and the safety
of the public without placing undue burdens on patients to get the treatment
they need for their health conditions.107 In sum, New York’s regulatory
system places substantial obstacles in the path of patients with qualifying
health conditions through its refusal to extend recommendation privileges to
other health care professionals besides physicians, its barriers to physicians
from acquiring recommendation privileges, its prohibition of out-of-state
physicians with recommendation privileges from recommending medical
cannabis in New York, and its lack of a complete published list of physicians
with recommendation privileges. Thus, restrictions of this kind ought to be
avoided to achieve the optimal regulatory system for distributing medical
cannabis to qualifying patients–that is, a system that makes it as simple as
102. 21 R.I. GEN. LAWS § 21-28.6-3(16) (2016).
103. Id.
104. VT. STAT. ANN. tit. 18, § 4472(6) (2012).
105. Owen, supra note 76.
106. Id.
107. AMA, supra note 41.

274

BELMONT LAW REVIEW

[Vol. 5: 253

possible for any health care professionals adequately trained and licensed to
obtain recommendation privileges in a way that is also visible to the public.
Additionally, the best regulatory system should incorporate an
extension of recommendation privileges to health care professionals beyond
physicians. Many of the qualifying medical conditions in the legalized states
are reasonably within the ability of health care professionals other than
physicians to diagnose.108 Chronic pain or nausea, for example, probably
does not require a licensed physician to diagnose.109 Thus, allowing physician
assistants or registered nurse practitioners to have recommendation
privileges for at least some qualifying medical conditions is likely to improve
efficiency in the medical cannabis corner of the health care industry, allowing
a greater number of qualifying patients to get medical cannabis in a faster
and easier way. Indeed, if a state did not want to allow non-physician health
care professionals to recommend medical cannabis for more complicated
diseases (e.g., cancer), then it could create exceptions in its regulatory
scheme for specific qualified health conditions that it deems more important
to have physicians diagnose. Any remaining qualifying health conditions that
are more easily diagnosed could trigger a statutory allowance for other health
care professionals to recommend medical cannabis as to those qualified
health conditions.
Moreover, the best regulatory system should provide for a public
disclosure of health care professionals with recommendation privileges to
give qualifying patients a better idea of which health care professionals they
can go to in order to receive a recommendation for medical cannabis. Many
qualifying patients have serious medical conditions, such as cancer or
terminal illness, and a public list of all health care professionals with
recommendation privileges could help improve the efficacy of the
distribution system because more patients will know which health care
professionals they can visit to get the recommendation they need to register
for a medical cannabis ID card, and patients will have more choices in
deciding which health care professional they wish to see.110 The alternative
to such a system would likely be riddled with problems similar to those which
New York is currently facing from its lack of a published list.111 Thus, patient
convenience and access could be greatly enhanced by such a public
disclosure.
Finally, the best regulatory system should incorporate reciprocity
provisions that allow health care professionals with recommendation
privileges in other states to recommend medical cannabis in the regulating
state, provided that the regulating state’s relevant provisions pertaining to
qualifying health care professionals are sufficiently similar to the provisions
108. What Roles Does a Nurse Practitioner Have?, NURSE JOURNAL, http://nursejournal
.org/nurse-practitioner/what-does-a-msn-nurse-practitioner-do (last visited Jan. 27, 2017).
109. Id.
110. Owen, supra note 76.
111. Id.
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of the states receiving reciprocity. While this may not have a large impact on
increasing the number of health care professionals with recommendation
privileges accessible to qualifying patients in state groupings that are large in
geographic area (e.g., Montana or Idaho), it has the potential to increase
patient access to health care professionals with recommendation privileges
in tighter state groupings (e.g., Maryland and Delaware or New York and
New Jersey), since privileged health care professionals in tighter state
groupings may be more likely to travel, live, or work in a cluster of states
where there may be shortages of particular types of health care services.112
G.

Variations Among the Legalized States Regarding Patient
Registration Requirements and State Reciprocity

All legalized states require some form of patient registration or
identification (ID) cards.113 Generally, once a qualifying patient has received
a recommendation from a privileged health care professional, the patient can
register with the state’s Department of Health in order to receive an ID card
which allows the patient to purchase medical cannabis at authorized places
of distribution.114 Registration usually requires the presentment of the
patient’s medical records (including the privileged physician’s
recommendation), a valid in-state photo ID (e.g., a driver’s license), and
proof of in-state residency.115 Registration lists or databases are usually
maintained by the state’s Department of Health and contain confidentiality
protections.116 If a patient wishes to renew their ID card upon expiration, or
if it is lost or stolen, she must generally acquire another recommendation
from a privileged health care professional and pay a renewal fee.117 One
major issue among legalized states is whether any given legalized state’s
regulatory system recognizes ID cards from other states and, if so, what the
legal significance of that recognition is. Another issue is the amount of
money a patient must pay to get an ID card and to annually renew the ID

112. Recent Studies and Reports on Physician Shortages in the US, ASS’N OF AM. MED.
COLLEGES, (2012), https://www.aamc.org/download/100598/data.
113. In Washington, however, patients with qualifying health conditions may purchase
medical cannabis without a “recognition card,” so long as they comply with the purchasing,
possession, and cultivation standards set out in the statute for individuals who do not register
in Washington’s database. WASH. REV. CODE. ANN. § 69.51A.210(3) (West 2016).
114. See MICH. COMP. LAWS ANN. § 333.26426(a) (West 2016).
115. Some states, such as Michigan, also allow voter registration cards in lieu of a
driver’s license. Presenting either document is considered sufficient proof of in-state
residency. Id.
116. See WASH. REV. CODE ANN. § 69.51A.230 (West 2015).
117. Provided that the patient’s card has been lost or stolen, Washington allows a
patient to get a new “recognition card” without getting another recommendation from a
privileged health care professional; however, if the patient does not get another
recommendation, the replacement “recognition card” will expire at the same time as the
original card would have. Id. § 69.51A.230(5).

276

BELMONT LAW REVIEW

[Vol. 5: 253

card. Finally, states may have additional requirements for minor patients and
their caregivers, including a higher registration fee.118
New York requires patients to pay a $50 registration fee in order to
get an ID card for medical cannabis, although the New York Department of
Health may waive the fee in cases of financial hardship.119 Additionally, New
York does not recognize ID cards from outside the state.120 Cardholding
patients in New York must pay $50 annually to renew their ID cards.121
Furthermore, a cardholding patient must receive another recommendation
from a privileged health care professional before he or she can renew their
ID card.122 New York does not allow for personal cultivation, so cardholding
patients may only purchase medical cannabis from dispensaries within the
state.123 Finally, recommended patients must be eighteen years of age or
assign a caregiver that is at least twenty-one years of age in order to acquire
an ID card.124
Oregon has a higher registration fee than New York, requiring
recommended patients to pay $200 in order to get an ID card for the purchase
of medical cannabis from dispensaries.125 Persons participating in the
Supplemental Nutrition Assistance Program (“SNAP”) are only required to
pay $60 to get an ID card, and persons receiving SSI benefits or who are
veterans are only required to pay $20 to get an ID card.126 An ID card in
Oregon allows for both purchase and personal cultivation.127 To get an ID
card, a qualifying patient must present proof of residency in Oregon, medical
records (including the privileged physician’s recommendation), and be
eighteen years of age, unless the patient designates at least one caregiver who
is a parent or legal guardian.128 ID cards must be renewed annually with an
additional privileged physician’s recommendation, and the fee for renewal is
$200.129 Oregon does not recognize ID cards from other states.130
Michigan has a $60 registration fee for both applications and
renewals of ID cards. A patient must be at least eighteen years of age, unless
the patient designates his parent or legal guardian as his primary caregiver
118. See ARIZ. ADMIN. CODE § R9-17-102 (2017).
119. N.Y. PUB. HEALTH LAW § 3363(2)(f).
120. N.Y. Dep’t of Health, Information for Patients, HEALTH.NY.GOV,
https://www.health.ny.gov/regulations/medical_marijuana/faq.htm (last visited Jan. 27,
2017).
121. N.Y. PUB. HEALTH LAW § 3361(7).
122. Id. § 3363(2)(a)(i).
123. AMA, supra note 41.
124. N.Y. PUB. HEALTH LAW § 3363(3).
125. Oregon Health Authority, OMMP Cardholder Fees, OREGON.GOV, http://www.
oregon.gov/oha/ph/DiseasesConditions/ChronicDisease/MedicalMarijuanaProgram/Pages/O
MMP-Fees.aspx (last visited June 22, 2017).
126. Id.
127. OR. ADMIN. R. 333-008-0020.
128. OR. REV. STAT. § 475B.415.
129. OR. REV. STAT. § 475B.415(6)(b); Oregon Health Authority, supra note 125.
130. OR. REV. STAT. § 475B.415.
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and the primary caregiver gets certifications from at least two privileged
physicians.131 The patient must also show proof of in-state residency for
every application or renewal.132 Another written certification from a
privileged physician is required every time a patient wants to renew his or
her ID card.133 A patient’s ID card must be renewed every two years. 134
Michigan does not offer discounts on application or renewal fees for poor
patients. Michigan allows for registered patients without caregivers to
personally cultivate up to twelve plants at a time.135 An interesting aspect of
Michigan’s regulatory system is that it recognizes ID cards from outside the
state, so long as that ID card is valid under the state laws of the state that
issued it. Valid out-of-state ID cards are legally recognized as if they had
been issued by the state of Michigan, and carry the same force and effect as
Michigan ID cards.136
Arizona has a $150 registration and renewal fee for its ID cards.137
Arizona requires registered patients to renew their ID cards annually.138 A
qualified patient must be at least eighteen years of age to obtain an ID card,
unless the patient designates his parent or legal guardian as his primary
caregiver and the patient receives two certifications from privileged
physicians.139 If the patient is under the age of eighteen and must designate
his parent or guardian as his primary caregiver, he must pay an increased
registration fee of $350 (renewal fees are also $350 in this case).140 For all
applications and renewals, the patient must present a new certification from
a privileged health care professional (or two certifications, if the patient is
under the age of eighteen).141
Additionally, all patients must present proof of in-state residency and
photo identification for registration or renewal.142 Qualifying patients of at
least eighteen years of age that are in the SNAP program only have to pay
$75 for registration or renewal fees, and qualifying patients under the age of
eighteen that are in the SNAP program only have to pay $275 for registration
or renewal fees.143 Patients over the age of eighteen and the primary
caregivers of patients under the age of eighteen may cultivate up to twelve
plants if they indicate on their application or renewal form that there is not a
dispensary within twenty-five miles of the patient’s home, provided the

131. MICH. COMP. LAWS ANN. 333.26426(b) (West 2016).
132. Id. § 333.26426(a)(6).
133. Id. § 333.26426(a)(1).
134. Id. § 333.26426(e).
135. Id. § 333.26424(a).
136. Id. § 333.26424(k).
137. ARIZ. ADMIN. CODE § R9-17-102 (2012).
138. Id. § R9-17-108(A).
139. ARIZ. REV. STAT. §§ 36-2804.02-.03 (2014).
140. ARIZ. ADMIN. CODE § R9-17-102.
141. ARIZ. REV. STAT. §§ 36-2804.02-.03.
142. Id. § 36-2804.02(A)(3)(a).
143. ARIZ. ADMIN. CODE § R9-17-102.
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Department of Health verifies that the information provided on the
application or renewal form is accurate.144 Finally, Arizona recognizes outof-state ID cards, provided that they are valid under the laws of the state in
which they were issued; however, valid out-of-state ID cards may not be used
to purchase medical cannabis at any Arizona dispensary (thus only protecting
card-carrying out-of-state patients from criminal penalties for possession of
medical cannabis).145
H.

The Ideal Regulatory System’s Rules Pertaining to Patient
Registration Requirements and State Reciprocity

As to the issues pertaining to registration, renewal, and reciprocity
of ID cards, the best regulatory system for distributing medical cannabis
should incorporate various elements found in New York, Oregon, Michigan,
and Oregon. First, the regulatory system should keep registration and renewal
fees as low as is practicable. New York’s low registration and renewal fee of
$50 is a good starting point, but the best regulatory system should seek to
lower the fee even more, since lowering the fee would increase patient access
to medical cannabis. Another positive aspect of New York’s regulatory
system that should be emulated in an ideal regulatory system is the ability of
the state to completely waive the fee for indigent patients. Rather than simply
lowering the cost of the fee for specific individuals (SNAP participants,
veterans, etc.), the ideal regulatory system should also provide for a complete
waiver of the fee for low-income patients. A showing of low-income should
not be overly difficult to prove; a showing of Medicaid eligibility or SNAP
eligibility should be sufficient.146 If the state cannot afford to completely
waive the fee for such individuals, it should make the fee as minimal as
possible to the extent that it is financially practicable. Indeed, to the extent
that patients cannot afford the fees necessary to obtain or renew the necessary
ID cards, the fundamental goal of allowing patients access to medical
cannabis to treat their health conditions is undermined, since patients will be
unable to purchase medical cannabis without an ID card. Additionally, the
best regulatory system should avoid charging higher registration or renewal
fees for minors (as Arizona does), because the caregivers of minor patients
(parents or legal guardians) are already managing the debilitating medical
conditions of their children.147 Imposing an extra cost on parents who are
already shouldering the burdens of treating their child’s medical conditions
is an unnecessarily depraved act, absent a compelling state financial need to
do so.

144. ARIZ. REV. STAT. § 36-2804.02(A)(3)(f).
145. Id. § 36-2804.03(C).
146. For example, Arizona lowers its registration fees if a qualifying patient participates
in SNAP. ARIZ. ADMIN. CODE § R9-17-102.
147. Id.

2018]

FLYING HIGH IN THE REGULATORY STATE

279

Second, the ideal regulatory system should allow for the automatic
right of personal cultivation of medical cannabis immediately upon the
issuance of an ID card, provided that the patient is at least eighteen years old.
If the patient is not eighteen years old and the ID card is instead procured
upon the designation of a caregiver, the caregiver should have the right to
personally cultivate medical cannabis on behalf of the minor-patient.
Geographic distance from dispensaries can provide a barrier to patient access
to medical cannabis in the absence of the ability to personally cultivate. 148
Thus, allowing for personal cultivation upon the issuance of an ID card can
help alleviate the challenges geographically isolated patients face.149
Further, allowing for personal cultivation increases patient choice
and even patient access to medical cannabis, since personal cultivation
allows for patients to conveniently retrieve medical cannabis within their
own home without spending time and money on travel to reach the nearest
dispensary. Some patients may even have debilitating medical conditions that
make it difficult for them to travel to dispensaries, and caregivers may not
always be available to procure the medical cannabis for patients to which
they are assigned; personal cultivation can alleviate these problems as well.
Lastly, the reasonably standardized system of ID cards adopted in legalized
states can sufficiently ensure that minor patients are not personally
cultivating medical cannabis through the restriction that only a minor
patient’s caregiver may cultivate medical cannabis. Thus, an automatic right
to personally cultivate medical cannabis upon the issuance of an ID card
would not pose a substantial enough risk of minors illegally cultivating
medical cannabis to outweigh the benefits of allowing automatic personal
cultivation. This strongly supports the notion of adopting a more unified body
of law, such as the Model Act in this Note, as doing so would help protect
minor children and the broader public.
Third, the best regulatory system should, at least in some cases,
require renewal of ID cards less frequently than annually. Michigan’s
regulatory system (requiring renewal every two years) takes a better
approach than Oregon’s, Arizona’s, or New York’s (all of which require
annual renewal), but it is still too standardized to be ideal. For example,
patients with qualifying medical conditions such as epilepsy or AIDS should
not be required to renew their ID cards every year, for several reasons. First,
qualifying medical conditions such as epilepsy or AIDS are currently
incurable. Patients with incurable conditions are using medical cannabis to
manage their health conditions on a permanent basis.150 While the renewal
process usually requires a new certification from a privileged physician on
an annual basis–presumably to check in on the patient’s continuing need for
medical cannabis–requiring annual renewal for patients with incurable
148. Morrison et al., The Economic Geography of Medical Marijuana Dispensaries in
California, 25 INT’L J. OF DRUG POLICY 508 (2014).
149. Id.
150. AMA, supra note 41.
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qualifying medical conditions does nothing but impose additional costs on
those patients. In addition to a patient with an incurable qualifying medical
condition having to pay for the renewal fee each year, the patient must also
pay for an additional doctor’s visit to a privileged health care professional to
receive a new certification for the renewal. Thus, the standardized
requirement that all qualifying patients (including patients with incurable
qualifying health conditions) renew their ID cards each year imposes undue
financial burdens and at least some unnecessary costs on unfortunate patients
with incurable qualifying health conditions.
In addition, cardholding patients with incurable conditions could
simply meet with a privileged physician as they need to–changes in their
medical condition or symptoms or desires for changes in their treatment plan
could prompt additional visits to physicians rather than a universal
requirement that they meet with a privileged physician once every year when
it may be unnecessary to do so. As a result, an ideal regulatory system should
impose more frequent renewal requirements only for those patients that have
qualifying medical conditions that are not incurable or unlikely to remain
constant. Third, cardholding patients with qualifying medical conditions that
are not incurable may still economically benefit from a longer issuing period
for their IDs because they would not have to pay as many renewal fees. In
sum, the best regulatory system for the distribution of medical cannabis to
patients should tailor its ID card issuing period to its list of qualifying medical
conditions instead of imposing a universal requirement. If a universal
requirement is unavoidable, the issuing period for ID cards should still be
longer than one year.
Another pillar of the best regulatory system for the distribution of
medical cannabis should constitute mandatory caregiver delegations for
qualifying patients who are minors. Furthermore, the ideal regulatory system
should include the requirement that caregivers for qualifying minor-patients
be the minor’s parent or legal guardian. All legalized states currently require
some person at least eighteen years of age to preside over the purchase,
cultivation, and treatment aspects of qualifying patients that are not yet
adults. Legalized states also generally require that the caregiver be either a
parent or guardian of the qualifying minor-patient. New York’s regulatory
system requires that a minor’s caregiver be at least twenty-one years old, but
this may not completely optimal. Most parents or legal guardians of
qualifying minor-patients will be twenty-one years old, but there may be
some situations where that is not the case.
Specifically, very young children sometimes use medical cannabis
for the treatment of severe epilepsy (usually after exhausting conventional
prescription drugs).151 There may be some situations in which a very young
child could have severe epilepsy as a qualifying medical condition and the
151. Epilepsy Foundation, Medical Marijuana and Epilepsy, EPILEPSY.COM,
http://www.epilepsy.com/learn/treating-seizures-and-epilepsy/other-treatmentapproaches/medical-marijuana-and-epilepsy (last visited July 7, 2017).
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child’s only parent is not yet twenty-one years of age. Assuming, arguendo,
that the child also has no extended family (such as grandparents) that could
assume the role of caregiver under the relevant state statute, the child would
be denied access to what could be his best or last hope in treating a severe
seizure disorder. In these narrow situations, the best regulatory system ought
to include either an exception to the requirement that the caregiver parent or
guardian be twenty-one years of age, or simply make the age requirement for
caregiver parents or guardians eighteen instead of twenty-one.
Setting aside the age requirement for caregivers, a state has an
especially strong interest in protecting the health and safety of children, and
medical cannabis should never be used to treat children without the approval
of both a privileged physician and the minor-patient’s parent or legal
guardian. Requiring the consent of parents or guardians in such situations,
and requiring the consenting parent or guardian to assume the duty of
becoming the child’s caregiver, ensures that children do not get access to
medical cannabis in situations the law does not allow. By requiring parents
or guardians to become caretakers for the minor-patient, minors are removed
from any cultivation and purchasing activities related to medical cannabis.
Thus, the state fulfills its interest in protecting children and reduces the risk
of illegal drug possession or trafficking resulting from allowing children to
use medical cannabis to treat their debilitating health conditions. While
mandatory caregiver provisions for qualifying minor-patients are an essential
element of the ideal regulatory scheme for distributing medical cannabis, a
regulating state should also take care to not impose extra fees on registration
and renewal of ID cards for qualifying patients who are minors.
Finally, the preeminent regulatory system for the distribution of
medical cannabis should include mandatory dual-certification from
privileged health care professionals for qualifying patients who are minors.
This dual-certification requirement should apply to both a qualifying minorpatient’s initial registration and to every renewal of the minor-patient’s ID
card. Because of the heightened state interest in protecting children, requiring
at least two privileged health care professionals to provide recommendations
before issuing the minor-patient an ID card under the supervision of a
caregiver parent or guardian is appropriate. The ideal regulatory system may
also want to include a requirement that the privileged health care
professionals issuing recommendations for children have a higher degree of
specialty (i.e. only allow licensed physicians recommendation privileges for
children rather than nurse practitioners or physician assistants).
CONCLUSION
The legalization of medical cannabis throughout the United States
has presented several key legal issues, and is likely to introduce more issues
as some states legalize cannabis for recreational use. From the ability of
health care professionals to recommend medical cannabis to the way a state
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creates and manages dispensaries for patients with qualifying medical
conditions, several states have already tried a multitude of approaches.
Thousands of patients around the nation now use medical cannabis to treat
dozens of health conditions, and some parents and physicians are boldly
using medical cannabis to try to treat sick children in innovative ways that
produce fewer negative results than conventional treatments.152
As more states legalize medical cannabis, the regulatory styles and
schemes concerning these issues will invariably mutate and shift in new and
interesting directions. Nevertheless, it remains clear that the best regulatory
system is a blend of the existing state experiments. The best regulatory
system for the distribution of medical cannabis must focus on expanding
patient access and choice while protecting the dignity and individual liberty
of patients so they can live the best lives in light of their unfortunate physical
circumstances. The first way this is best accomplished is by having an
expansive list of qualifying medical conditions with the potential for growth
so any medical condition which a physician believes medical cannabis could
help alleviate can be legally treated with medical cannabis. Second, an
effective regulatory system for distributing medical cannabis must allow for
generous personal cultivation and easily- and cheaply-established
dispensaries so market competition improves the effective delivery of
medical cannabis to patients while reducing its price and lessening a patient’s
burden on acquiring it.153 Third, the ideal regulatory system must allow
recommendation privileges to a broad swath of health care professionals that
are easily identified and accessed by qualifying patients to ensure that
patients know who they can go to in order to discuss the possibility of using
medical cannabis as a treatment in a timely manner. Finally, the best
regulatory system must break down the barriers of patient registration by
reducing the cost of application and renewal and providing for generous
reciprocity between and among the various state registration systems.
If these processes are implemented correctly, states can effectively
protect the public in the face of legalized medical cannabis while ensuring
that those who are most sick in our society have easy, effective, fast, cheap,
and safe access to an incredible treatment that our society is just beginning
to understand. The evolving decency of our society demands an end to the
unwarranted attacks on the dignity of dying patients who use medical
cannabis as nothing more than an effort to experience a brief reprieve from
their quiet desperation and physical torment. If an individual can derive
medical benefit from the use of cannabis, our constitutional system of
ordered liberty affords that individual the right to use it.

152. Boyd, supra note 27.
153. SMITH, supra note 78.

